BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2005
 |  BioCentury  |  Finance

Tysabri hangover

The suspension of multiple sclerosis compound Tysabri natalizumab from Biogen Idec Inc. and Elan Corp. plc was the story of the first quarter and certainly did its part to send the BioCentury 100 Index down 14%. The decline had the dubious distinction of topping the charts, ahead of an 8% fall by NASDAQ and 3% drops for the Dow Jones and S&P 500 (see "Index Performance").

Despite the presence of BIIB (Cambridge, Mass.) and ELN (Dublin, Ireland) in the top...

Read the full 387 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >